Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

HIV 101: HIV Vaccine Candidates

October 2001

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Adapted from Johnston M.I., Flores J. Progress in HIV Vaccine Development. Current Opinion in Pharmacology. 2001:1(5):504-520. On the Web at www.niaid.nih.gov/daids/vaccine/pdf/pc1506.pdf. Additional information from Science Magazine 2001 293 (5537): 1973.

As drug-resistant HIV virus becomes more and more common, physicians will need alternative methods of treating the virus. One of the most promising of these methods is the development of a prophylactic or therapeutic vaccine. The following table provides information on vaccines currently in the development pipeline.


Vaccine Name

HIV Subtype TargetedProducing CompanyStatus
gp120B/B, B/EVaxGenOngoing phase III trials in the United States and Thailand
ALVAC-HIVB, EAventis PasteurOngoing phase II trials in the U.S., Haiti, Brazil, Trinidad (subtype B); Thailand (sub-type E); used alone or in combination with gp120
ALVAC-HIVAAventis PasteurReady for Phase I trials in Uganda
Lipopeptides LP5, LP6BANRS: National Agency for AIDS Research, FranceOngoing phase I trials in France
Vaccinia TBC-3BBTherionOngoing phase I trials in the U.S.
DNA-HIVBApolionCompleted phase I trials
DNA-HIV, MVA-HIVAUniversity of OxfordOngoing phase I trials in the UK and Kenya
NYVAC-HIVBAventis PasteurReady for phase I in the U.S.
DNA-HIV, Adenovirus HIVBMerckOngoing phase I trials in the U.S.
VaxGen Canarypox with HIV gag, protease, and env +gp120B/EU.S. Military, Royal Thai Govt., Mahidol U., Aventis Pasteur, VaxGenEarliest phase III start date: Summer 2002, Thailand*
Canarypox with HIV env, gag, protease, pol, and nef, +gp120B/?NIH HVTN, Aventis Pasteur, VaxGenEarliest phase III start date: December 2002, U.S., Brazil, Haiti, Peru, Trinidad (Possible: Argentina, Dominican Republic, Honduras)*
* Proposed AIDS vaccine efficacy trials (see "News Flashes").

Advertisement
phase I trial: first stage trial, focusing on safety and toxicity, very small cohort.

phase II trial: second stage trial, measures efficacy of vaccine in small cohort.

phase III trial: last stage of experimental testing, pivotal trial measures efficacy on a larger scale.

gp120: recombinant HIV envelope protein.

ALVAC-HIV: a recombinant canarypox virus expressing multiple HIV genes.

MVA-HIV: modified vaccinia Ankara (an attenuated vaccinia vector) expressing multiple HIV genes.

NYVAC-HIV: an attenuated vaccinia vector expressing multiple HIV genes.

TBC-3B: an attenuated vaccinia vector expressing multiple HIV genes.


Back to the HEPP News October 2001 contents page.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

This article was provided by Brown Medical School. It is a part of the publication HEPP News.
 
See Also
More on Preventive HIV Vaccines
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

Tools
 

Advertisement